Contact Us

Global Attention Deficit Hyperactivity Disorder ADHD Therapeutics Analysis 2025, Forecast To 2034

24 Mar, 2025

What Fueled The Previous Growth In The Attention Deficit Hyperactivity Disorder ADHD Therapeutics Market?

The attention deficit hyperactivity disorder adhd therapeutics market has seen considerable growth due to a variety of factors.
• The market size of therapeutics for attention deficit hyperactivity disorder (ADHD) has demonstrated significant growth recently. It's projected to expand from $13.21 billion in 2024 to $14.1 billion in 2025, with a compound annual growth rate (CAGR) of 6.7%.
Factors such as increased awareness and diagnostic screening programs, a higher frequency of ADHD cases, developments in treatment methods, the improvement of healthcare infrastructure, and extended health insurance coverage have contributed to this growth during the historic period.

What Is The Expected Growth In The Attention Deficit Hyperactivity Disorder ADHD Therapeutics Market Size Evolve over the Forecast Period?

The attention deficit hyperactivity disorder adhd therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• The market for therapeutics in attention deficit hyperactivity disorder (ADHD) is projected to witness significant expansion in the upcoming years, escalating to a value of $17.25 billion in 2029 with a CAGR of 5.2%.
Several factors contributing to this growth during the forecast period include advancements in genetic research and personalized medicine, an increased recognition of mental health issues and international and national mental health campaigns, the spread of telehealth services, and the inclusion of behavioral therapies. The forecast period will also see notable trends such as innovative developments in treatment technology, efforts in research and development, the incorporation of digital therapeutics, strategies in precision medicine, and advancements in drug delivery systems.

What Main Forces Are Fueling Expansion In The Attention Deficit Hyperactivity Disorder ADHD Therapeutics Market?

The surge in the attention-deficit hyperactivity disorder (ADHD) incidences foretells a robust growth in the attention-deficit hyperactivity disorder (ADHD) therapeutics market. The phrase "escalating prevalence of ADHD" references the increasing diagnosis of this neurodevelopmental ailment across time. ADHD treatments tackle the condition's complex essence, striving to enhance symptom control, functional hindrance, life quality, and overall prosperity for people grappling with ADHD. For instance, Guardian, a news publisher based in the US, indicated in January 2023 reports that an approximated 170,000 identified patients received prescriptions for ADHD in 2022, marking a 20.4% rise from the 141,000 identified patients during the matching period of 2021. Thus, the growing prevalence of ADHD fuels the expansion of the attention-deficit hyperactivity disorder (ADHD) therapeutic market.

What Are The Primary Segments In The Global Attention Deficit Hyperactivity Disorder ADHD Therapeutics Market?

The attention deficit hyperactivity disorder (ADHD) therapeutics market covered in this report is segmented –
1) By Drug Type: Stimulants, Non-Stimulants
2) By Psychotherapy: Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy
3) By Age Group: Pediatric And Adolescent, Adult
4) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, E-Commerce Subsegments:
1) By Stimulants: Amphetamine-Based Stimulants, Methylphenidate-Based Stimulants
2) By Non-Stimulants: Atomoxetine, Guanfacine, Clonidine

Pre-Book The Attention Deficit Hyperactivity Disorder ADHD Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:

How Are Emerging Trends Reshaping The Dynamics Of The Attention Deficit Hyperactivity Disorder ADHD Therapeutics Market?

Top-tier businesses in the attention-deficit hyperactivity disorder (ADHD) therapeutics industry are turning their focus towards developing digital modernizations like Endeavor OTC versions of digital therapeutics for ADHD, to cater to the growing demand for digital approaches and rising need for remote health services. Digital therapeutics refer to evidence-based medical interventions that utilize high-quality software programs focused on preventing, managing, or treating medical disorders or illnesses. These treatments are designed to work independently or in conjunction with traditional medical treatments. For example, Akili, an American digital healthcare firm, unveiled an over-the-counter (OTC) version of its digital therapeutic video game aimed at adults with ADHD in June 2023. EndeavorOTC, the OTC version, is designed to enhance attention, time management, and organizational abilities. This action was taken in response to the success of Akili's FDA-authorized prescription video game treatment, EndeavorRx, intended for children with ADHD. The OTC version provides a non-pharmacological treatment alternative for adults who want to manage their ADHD symptoms.

Who Are the Key Players In The Attention Deficit Hyperactivity Disorder ADHD Therapeutics Market?

Major companies operating in the attention deficit hyperactivity disorder (ADHD) therapeutics market are:
• Pfizer Inc.
• Johnson And Johnson Services Inc.
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical's
• Eli Lilly and Company
• Otsuka Pharmaceutical Co. Ltd.
• UCB S.A.
• Amneal Pharmaceuticals LLC
• Lupin Ltd.
• Mallinckrodt Pharmaceuticals Inc.
• Hisamitsu Pharmaceutical Co. Inc.
• Purdue Pharma L.P.
• Arbor Pharmaceuticals LLC
• Tris Pharma Inc.
• NEOS Therapeutic Inc.
• Concert Pharmaceuticals Inc.
• Vayarin AG
• Rhodes Pharmaceuticals L.P.
• KemPharm Inc.
• Impax Laboratories Inc.
• Aevi Genomic Medicine
• Adlon Therapeutics L.P.
• Ironshore Pharmaceuticals Inc.
• Highland Therapeutics Inc.

What Is The Most Dominant Region In The Attention Deficit Hyperactivity Disorder ADHD Therapeutics Market?

North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.